Journal article
Cause and Timing of Death and Subgroup Differential Effects of Erythropoietin in the EPO-TBI Study
MB Skrifvars, C French, M Bailey, J Presneill, A Nichol, L Little, J Durantea, O Huet, S Haddad, Y Arabi, C McArthur, DJ Cooper, R Bellomo
Journal of Neurotrauma | MARY ANN LIEBERT, INC | Published : 2018
Abstract
The EPO-TBI study randomized 606 patients with moderate or severe traumatic brain injury (TBI) to be treated with weekly epoetin alfa (EPO) or placebo. Six month mortality was lower in EPO treated patients in an analysis adjusting for TBI severity. Knowledge of possible differential effects by TBI injury subtype and acute neurosurgical treatment as well as timing and cause of death (COD) will facilitate the design of future interventional TBI trials. We defined COD as cerebral (brain death, cerebral death with withdrawal, or death during maximal care) and non-cerebral (death following withdrawal or during maximal care, which had a non-cerebral cause). The study included 305 patients treated ..
View full abstractGrants
Awarded by GE Healthcare
Funding Acknowledgements
EPO-TBI was supported by grants from the National Health and Medical Research Council of Australia (grant 545902) and the Transport Accident Commission of Victoria (grant D162). Markus Skrifvars has received personal research funding from Medicinska Understodsforeningen Liv och Halsa, Finska Lakaresallskapet, and Svenska Kulturfonden. Alistair Nichol has received support from the Health Research Board of Ireland.